Abstract
The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Volume: 13 Issue: 2
Author(s): Ioannis Legakis and Konstantinos Syrigos
Affiliation:
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Abstract: The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Export Options
About this article
Cite this article as:
Legakis Ioannis and Syrigos Konstantinos, Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715303112129990027
DOI https://dx.doi.org/10.2174/18715303112129990027 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells
Recent Patents on Anti-Cancer Drug Discovery Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Pharmacokinetics and Disposition of Various Drug Loaded Biodegradable Poly(Lactide-Co-Glycolide) (PLGA) Nanoparticles
Current Drug Metabolism Recent Applications of Grape Polyphenols in Foods, Beverages and Supplements
Recent Patents on Food, Nutrition & Agriculture The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Potential Novel Targets in Breast Cancer
Current Pharmaceutical Biotechnology Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry